Eleanor Carlyle
A5005076029- Cancer Genomics and Diagnostics
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- SARS-CoV-2 and COVID-19 Research
- Computational Drug Discovery Methods
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- Cell Image Analysis Techniques
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- CAR-T cell therapy research
- Renal cell carcinoma treatment
- Molecular Biology Techniques and Applications
- Virus-based gene therapy research
- Prostate Cancer Treatment and Research
- Immune Cell Function and Interaction
- Ocular Oncology and Treatments
- Protein Degradation and Inhibitors
- Radiomics and Machine Learning in Medical Imaging
- Breast Cancer Treatment Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Genomics and Chromatin Dynamics
- Long-Term Effects of COVID-19
- Pancreatic and Hepatic Oncology Research
Royal Marsden NHS Foundation Trust
2021-2024
The Francis Crick Institute
2024
Royal Marsden Hospital
2021-2023
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indirectly correlates clinical T receptor (TCR) analysis reveals significantly higher number expanded TCR...
Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is prospective cohort study of COVID-19 immunity patients with cancer. Here we evaluated 585 following administration two doses BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after were 85% and 59% solid hematological malignancies, respectively. A lower proportion had detectable titers neutralizing antibodies (NAbT) against severe acute...
Abstract Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported vaccines and is an extremely rare immune-related adverse event immune checkpoint inhibitors. We present a case CRS that occurred 5 d after BTN162b2 (tozinameran)—the Pfizer-BioNTech COVID-19 vaccine—in patient colorectal on long-standing anti-PD-1 monotherapy. The was...
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling clinical annotation. Of 357 patients cancer, 118 were SARS-CoV-2 positive, 94 symptomatic 2 died of COVID-19. In this cohort, 83% had S1-reactive antibodies 82% neutralizing against wild type SARS-CoV-2, whereas antibody titers Alpha, Beta Delta variants substantially reduced. levels decreased in 13% patients, remained stable for up to...
Abstract Understanding the evolutionary pathways to metastasis and resistance immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present most comprehensive intrapatient metastatic dataset assembled date as part of Posthumous Evaluation Advanced Cancer Environment (PEACE) research autopsy program, including 222 exome sequencing, 493 panel-sequenced, 161 RNA 22 single-cell whole-genome sequencing samples from 14 ICI-treated patients. We observed...
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and severe disease. In the context CAPTURE study (NCT03226886), we report in 80 patients who received fourth dose BNT162b2. We measured neutralizing antibody titers (NAbTs) using live virus microneutralization assay against wild-type (WT), Delta, Omicron BA.1 BA.2 T cell WT an activation-induced marker (AIM) assay. The proportion detectable NAb after increased...
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling clinical annotation. Of 357 patients cancer, 118 were SARS-CoV-2-positive, 94 symptomatic 2 died of COVID-19. In this cohort, 83% had S1-reactive antibodies, 82% neutralizing antibodies against WT, whereas antibody titers (NAbT) Alpha, Beta, Delta variants substantially reduced. Whereas levels decreased in 13% patients, NAbT...
Abstract Background: Although a range of therapeutic options are available in the management invasive breast carcinomas, spatial segregation tumour subclones has hampered biomarker identification single-region samples. Representative sampling (RS) overcomes bias by from homogenized and well-mixed cancer specimen. The Homogenization Leftover Surgical Tissue Feasibility Study (HoLST-F - NCT03832062) is prospective trial aiming to assess feasibility RS tumor tissue leftover after pathology...
Abstract Diverse clinical presentations of clear cell renal carcinoma (ccRCC) confound decision making, leading to over and undertreatment. Clonal evolution ccRCC proceeds through distinct trajectories characterised by differing levels genomic intratumoral heterogeneity (gITH) chromosomal complexity (weighted instability index, wGII). However, accurate evaluation these indices requires multiregional profiling fresh tumour; cost prohibitive logistically challenging in the setting. Clinical...
<div>Abstract<p>Understanding the evolutionary pathways to metastasis and resistance immune checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here we present most comprehensive intra-patient metastatic dataset assembled date as part of PEACE research autopsy programme, including 222 exome, 493 panel-sequenced, 161 RNA-seq, 22 single-cell whole-genome sequencing samples from 14 ICI-treated patients. We observed frequent doubling widespread loss...
<p>Supplementary figure 1: Cohort overview. Number of samples sequenced with whole exome, panel or RNA sequencing. Supplementary 2: Phylogeny and WGD events in CRUKP1047. 3: Ploidy SCNA burden. 4: Overview each case. 5: MEDICC2 copy number sample trees. 6: MEDICC tree all exome demonstrating that cluster together by patient, not melanoma subtype. 7: frequency cutaneous (a), acral (b) unknown primary (MUP, c). 8: Correlation between liver distance to other sites time emergence after...
<p>Supplementary figure 1: Cohort overview. Number of samples sequenced with whole exome, panel or RNA sequencing. Supplementary 2: Phylogeny and WGD events in CRUKP1047. 3: Ploidy SCNA burden. 4: Overview each case. 5: MEDICC2 copy number sample trees. 6: MEDICC tree all exome demonstrating that cluster together by patient, not melanoma subtype. 7: frequency cutaneous (a), acral (b) unknown primary (MUP, c). 8: Correlation between liver distance to other sites time emergence after...
Abstract CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 following administration two doses BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after were 85% and 59% solid hematological malignancies, respectively. A lower proportion had detectable neutralizing antibody titers (NAbT) against SARS-CoV-2 variants concern (VOCs) vs wild-type (WT). Patients malignancies more likely to have...
Abstract Not all patients with cancer, in particular those hematogic malignancies, develop functional immunity against SARS-CoV-2 variants of concern (VOC) following COVID-19 vaccines. Durability vaccine-induced after two doses and the impact a third dose were evaluated CAPTURE (NCT03226886), longitudinal prospective cohort study vaccine responses cancer. In evaluating 316 patients, at median 111 days either BNT16b2 or ChadOX, we observed time-dependant decline neutralising antibody titres...
<p>Supplementary figure 1: Cohort overview. Number of samples sequenced with whole exome, panel or RNA sequencing. Supplementary 2: Phylogeny and WGD events in CRUKP1047. 3: Ploidy SCNA burden. 4: Overview each case. 5: MEDICC2 copy number sample trees. 6: MEDICC tree all exome demonstrating that cluster together by patient, not melanoma subtype. 7: frequency cutaneous (a), acral (b) unknown primary (MUP, c). 8: Correlation between liver distance to other sites time emergence after...
<div>Abstract<p>Understanding the evolutionary pathways to metastasis and resistance immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present most comprehensive intrapatient metastatic dataset assembled date as part of Posthumous Evaluation Advanced Cancer Environment (PEACE) research autopsy program, including 222 exome sequencing, 493 panel-sequenced, 161 RNA 22 single-cell whole-genome sequencing samples from 14 ICI-treated patients....